Leadership Team
Meet our experienced team.
A well designed linker helps the antibody to selectively deliver and release the drug to the tumor site. Our tailored solutions identify and de-risk your clinical candidates for development ensuring stage-specific milestones are met. By applying our expertise in highly potent small molecule process development, we utilize a Design of Experiment (DOE) based approach. Our capabilities include:
We are dedicated to advancing the frontiers of medicine through our specialized linker payload solutions for bioconjugates and ADCs. Our comprehensive suite of services encompasses everything from precise payload design to GMP manufacturing, backed by a deep understanding of monoclonal antibodies and innovative linker technologies.
To accelerate lead drug candidate selection, we apply our knowledge in linker payload design and synthesis, high potency materials, and analytical method development to develop your complex ADCs.
Linker-payload processes are developed and transferred directly to our cGMP manufacturing team minimizing challenges seen during process transfers.
We develop the most effective processes for manufacturing at toxicology, clinical, and commercial scale using quality by design (QbD) principles.
Processes follow ICH Product Lifecycle guidelines which ensure a robust and well characterized scalable manufacturing process.
Utilizing analytics, we ensure the right product quality attributes for your program.
The asset you’re developing right now can make a real difference for human health. Let us apply our wealth of experience to accelerate and maximize its potential.